BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34903133)

  • 41. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis.
    Zheng C; You W; Wan P; Jiang X; Chen J; Zheng Y; Li W; Tan J; Zhang S
    Medicine (Baltimore); 2018 Jun; 97(25):e11004. PubMed ID: 29923984
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of radiographic and prognostic characteristics of programmed death-ligand 1 expression in high-grade gliomas.
    Ohno M; Kitano S; Satomi K; Yoshida A; Miyakita Y; Takahashi M; Yanagisawa S; Tamura Y; Ichimura K; Narita Y
    J Neurooncol; 2022 Nov; 160(2):463-472. PubMed ID: 36282354
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic and clinicopathological roles of programmed death-ligand 1 (PD-L1) expression in thymic epithelial tumors: A meta-analysis.
    Koh HM; Jang BG; Lee HJ; Hyun CL
    Thorac Cancer; 2020 Nov; 11(11):3086-3098. PubMed ID: 32926538
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.
    Wang Z; Peng S; Xie H; Guo L; Cai Q; Shang Z; Jiang N; Niu Y
    Clin Exp Med; 2018 May; 18(2):165-175. PubMed ID: 29362922
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma.
    Yi K; Cui X; Liu X; Wang Y; Zhao J; Yang S; Xu C; Yang E; Xiao M; Hong B; Fang C; Kang C; Tan Y; Wang Q
    Front Immunol; 2021; 12():802795. PubMed ID: 35069587
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
    Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
    Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis.
    Gao HL; Liu L; Qi ZH; Xu HX; Wang WQ; Wu CT; Zhang SR; Xu JZ; Ni QX; Yu XJ
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):95-100. PubMed ID: 29576277
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis.
    Ma G; Deng Y; Jiang H; Li W; Wu Q; Zhou Q
    Clin Chim Acta; 2018 Jul; 482():101-107. PubMed ID: 29614306
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis.
    Ni X; Sun X; Wang D; Chen Y; Zhang Y; Li W; Wang L; Suo J
    Clin Transl Oncol; 2019 May; 21(5):674-686. PubMed ID: 30392153
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Correlation of immune phenotype with IDH mutation in diffuse glioma.
    Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
    Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Good prognostic factor in patients with nonmetastatic nasopharyngeal carcinoma: Programmed death ligand-1 expression in tumor cells.
    Sahinli H; Akyürek N; Yılmaz M; Kandemir O; Duran AO; Kulaçoǧlu S; Uçar G; Acar E; Özet A; Öksüzoǧlu OBÇ; Özdemir NY
    J Cancer Res Ther; 2020 Dec; 16(Supplement):S43-S47. PubMed ID: 33380650
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data.
    Matikas A; Zerdes I; Lövrot J; Richard F; Sotiriou C; Bergh J; Valachis A; Foukakis T
    Clin Cancer Res; 2019 Sep; 25(18):5717-5726. PubMed ID: 31227501
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients.
    Ludovini V; Bianconi F; Siggillino A; Vannucci J; Baglivo S; Berti V; Tofanetti FR; Reda MS; Bellezza G; Mandarano M; Belladonna ML; Metro G; Chiari R; Sidoni A; Puma F; Minotti V; Roila F
    Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33671892
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy.
    Zhang F; Zhu X; Zhang Q; Zhou P; Hao L
    Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.
    Qiu XY; Hu DX; Chen WQ; Chen RQ; Qian SR; Li CY; Li YJ; Xiong XX; Liu D; Pan F; Yu SB; Chen XQ
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1754-1769. PubMed ID: 29510196
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
    Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ
    Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic role and clinical significance of tumor-infiltrating lymphocyte (TIL) and programmed death ligand 1 (PD-L1) expression in gastric cancer: a systematic review and meta-analysis.
    Ren J; He Q; Yin H; Zheng L; Li L; Wu X
    Clin Transl Oncol; 2023 May; 25(5):1436-1445. PubMed ID: 36528835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis.
    Xu J; Zhao J; Wang J; Sun C; Zhu X
    Medicine (Baltimore); 2021 Apr; 100(14):e25318. PubMed ID: 33832106
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.
    Zhang M; Li G; Wang Y; Wang Y; Zhao S; Haihong P; Zhao H; Wang Y
    Sci Rep; 2017 Aug; 7(1):10255. PubMed ID: 28860576
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients.
    Xia H; Shen J; Hu F; Chen S; Huang H; Xu Y; Ma H
    Clin Chim Acta; 2017 Jun; 469():191-194. PubMed ID: 28188721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.